Natalia P. Beliak

Natalia P. Beliak

Auto-generated profile, based on publicly available information

Natalia P. Beliak

St. Petersburg State University; City Clinical Oncology Dispensary

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
GRG.A. Raskin
G.A. Raskin
MMM.S. Mukhina
M.S. Mukhina
EKE.D. Kravtsova
E.D. Kravtsova
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
STSergei Tjulandin
Sergei Tjulandin
ROR.V. Orlova
R.V. Orlova
Оценка статуса FGFR2 при раке желудка — важная задача, без прояснения которой нельзя выделить когорту пациентов, у которых можно было бы получить наилучший ответ на лечение анти-FGFR2-препаратами. ЦЕЛЬ ИССЛЕДОВАНИЯ Провести сравнительный анализ экспрессии и амплификации гена FGFR2 при раке желудка в первичных опухолях и метастазах в лимфатических узлах. МАТЕРИАЛ И МЕТОДЫ Статус FGFR2 был изучен у 61 больного с аденокарциномой желудка III стадии с использованием иммуногистохимического метода (Abcam clone EPR24075-418, R&D clone 98706, Santa Cruz clone C-8, Abcam clone 1G3) и флюоресцентной гибридизации in situ (FISH). Было проведено сравнительное исследование первичных опухолей и метастазов в лимфатических узлах. РЕЗУЛЬТАТЫ Удовлетворительным для иммуногистохимического исследования FGFR2 было признано антитело Abcam clone EPR24075-418. Экспрессия FGFR2 была выявлена в 26 (43%) случаях, амплификация — в 5 (8%). Амплификация FGFR2 в 4 случаях из 5 сопровождалась экспрессией 3+, в 1 случае — 2+. Дискордантность между первичной опухолью и метастазом выявлена в 13 (21%) случаях. ЗАКЛЮЧЕНИЕ Клон EPR24075-418 показал наилучший результат в оценке экспрессии FGFR2: корреляция с результатами FISH при реакции 3+ составила 100%. Ввиду высокой гетерогенности экспрессии FGFR2 для ее оценки рекомендуется либо исследовать материал первичной опухоли и метастаза, либо оценивать большой объем первичной опухоли.

28 June 2021 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
SKS. I. Kutukova
S. I. Kutukova
NBN. P. Belyak
N. P. Belyak
YIYu. V. Ivaskova
Yu. V. Ivaskova
Прогностическая роль факторов системного воспаления в течении плоскоклеточного рака слизистой оболочки полости рта

19 December 2020 in Parodontologiya
Verified
Journal Article
Closed access
PDF file
SKS. I. Kutukova
S. I. Kutukova
NBN. P. Beliak
N. P. Beliak
GRG. A. Raskin
G. A. Raskin
MMM. S. Mukhina
M. S. Mukhina
YIYu. V. Ivaskova
Yu. V. Ivaskova
ARAlexandra Razumova
Alexandra Razumova
Relevance. Prognostic value of PD-L1 expression in oral cavity squamous cell carcinoma (OCSCC) and its effect on survival is still controversial. It should be to determine the prognostic role of PD-L1 expression on tumor and immune cells of OCSCC and assess their effect on overall survival (OS) and progression-free survival (PFS).Materials and methods. A prospective study included 145 patients, first diagnosed with OCSCC. PD-L1 expression on tumor and immune cells, infiltrating tumor and its microenvironment, was assessed in all tumor samples by IHC, CPS was calculated. Cut-off values were determined by ROC analysis for identification of PD-L1 expression effect on OS and PFS.Results. Most patients with oral mucosa squamous cell carcinoma showed positive expression of PD-L1 on tumor (77.2%) and immune cells (92.4%). The median PD-L1 expression on tumor cells was 13.5% [1.0-40.0], the median PD-L1 expression on immune cells was 5.0% [1.0-11.0], and the median CPS – 18.0 [3.0-7.8]. Univariate and multivariate analyses revealed a significant negative effect of PD-L1 expression on immune cells ≤ 7% on OS (HR 0.66; 95% CI 0.45-0.93; p = 0.0498); PD-L1 expression in tumor cells ≤ 15% (HR 0.65; 95% CI 0.43-0.98; p = 0.0416) and CPS ≤ 21 (HR 0.62; 95% CI 0.44-0.92; p = 0.0183) for PFS. PD-L1 expression in tumor cells ≤ 6% (HR 0.71; 95% CI 0.47-1.08; p = 0.1096) and CPS ≤ 7 (RR 0.67; 95% CI 0.44-1.01; p = 0.0575) had a confident tendency to negative impact on OS.Conclusion. Positive PD-L1 expression in tumor and immune cells as well as CPS are effective additional factors in the prognosis of the disease course, OS and PFS in patients with OCSCC.

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKSvetlana Kutukova
Svetlana Kutukova
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
NBNatalia P. Beliak
Natalia P. Beliak
JIJulia V. Ivaskova
Julia V. Ivaskova
ARAlexandra Razumova
Alexandra Razumova
E18023 Background: We investigated the prevalence of rare genes rearrangements in salivary gland adenocarcinomas and the impact of these fusions on overall survival (OS) and progression free survival (PFS). Methods: For 51/60 (85.0%) patients with different types salivary gland adenocarcinomas (stage I-IVA), sufficient tumor tissue was available for molecular characterization by polymerase chain reaction (PCR) and has been tested for NTRK, ALK, ROS1, RET and MET deletion. OS and PFS curves were estimated with the Kaplan-Meier method and compared using the log-rank test. Results: Two cases (3.92%) of NTRK translocation were found, both are a classic rearrangement of ETV6ex5; NTRK3ex15. Of the other alterations, 2 cases (3.92%) of unbalanced ALK expression. However, it was not possible to establish the option of rebuilding. In addition, were found 2 cases (3.92%) of highly balanced expression of NTRK2 and ALK, and one case (1.96%) of high expression of ROS1. RET mRNA expression was detected in 13 of 48 cases (27.08%). NTRK, RET, ALK and ROS1 fusions were equally common in both men and women (p = 0.89), not depending on age (0.76). All patients bearing ALK, RET and NTRK fusions had shorter overall survival - 13.2 months, 95% confidence interval [CI] 13.0 to 32.0 months in multivariable model 105.0 moth (95% CI 105.0-105.0) in patient's group without mutations (p = 0.1817); and shorter PFS: 5.0 month (95% CI 5.0-16.0) vs not reached PFC in group (mean of PFS 63.15±5.58; 95% CI 52.20-74.09) without mutations (p = 0.0467). ALK fusion is an independent poor prognosis factor affecting on OS: p = 0.0168, hazard ratio (HR) = 8.65 (95% CI 1.47-50.77); and poor prognosis factor affecting on PFS: p = 0.0170, HR = 7.13 (95% CI 1.42-35.80). Conclusions: ALK, NTRK, ROS1 and RET mutations define a new rare subtype of salivary gland adenocarcinomas with enormously poor prognosis. The presence ALK-mutation is an independent poor prognosis factorб negatively affecting both overall survival and progression-free survival. It’s advisable to consider the possibilities of using ALK, NTRK and RET inhibitors in this cohort of patients.

18 December 2024 in Malignant tumours
Verified
Journal Article
Open access
PDF file
ROR. V. Orlova
R. V. Orlova
AAA. V. Androsova
A. V. Androsova
ETE. E. Topuzov
E. E. Topuzov
NBN. P. Belyak
N. P. Belyak
SKS. I. Kutukova
S. I. Kutukova
GRG. A. Rakhimova
G. A. Rakhimova
Breast angiosarcoma is a rare malignancy that accounts for less than 0.5% of all breast cancers. The disease is characterized by rapid growth, aggressive course, active dissemination of the process and poor response to treatment. The peculiarity of the disease lies in the complexity of diagnosing the process, since the clinical picture is not specific and often occurs under the guise of skin diseases such as eczema, atopic dermatitis, rosacea, etc. Also, the complexity of diagnosis is complemented by the lack of specific imaging methods, thanks to which it would be possible to diagnose angiosarcoma with high accuracy. The leading element of treatment is a combined approach, namely a combination of surgical excision, drug therapy and radiation. This article presents our own experience in managing a patient with angiosarcoma of the right breast, which arose 7 years after the treatment of breast carcinoma in the St. Petersburg City Clinical Oncology Center.

7 August 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ROR. V. Orlova
R. V. Orlova
EKE. A. Kaledina
E. A. Kaledina
AMAnna Malkova
Anna Malkova
NZNatalia Zhukova
Natalia Zhukova
PNP. A. Naymushina
P. A. Naymushina
ATA. V. Tarasov
A. V. Tarasov
The COVID-19 pandemic has affected all medical fields and brought up a lot of serious problems. The features of the COVID-19 infection in patients with cancer are important to understand. According to many articles, patients with cancer are more vulnerable to COVID-19 infection. Patients undergoing anticancer treatment have 1-4% morbidity rate. Patients with hematological diseases and lung cancer are at higher risk of SARS-CoV-2 infection and also have more severe symptoms and complications. In this article we discuss the effect of the tumors on the immune system and comprehend the pathogenesis of the coronavirus disease according to its impact on the immunity. Moreover, in the review we analyze available data about the influence of the different types of cancer therapy (chemotherapy, target therapy, radiotherapy and immunotherapy) on the severity of the COVID-19 infection. Evidence on the effect of chemotherapy on severity and mortality from COVID-19 is contradictory. Whereas there are some authors concluding that chemotherapy treatment is not affecting the severity of COVID-19 disease, there are also some works where the connection between these facts was established. At the same time target therapy, radio- and immunotherapy most likely do not worsen the SARS-CoV-2 infection and are not associated with the development of complications. But it’s important to say that the amount of data available for today is insufficient to make a unambiguous conclusion.